Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

McGill University

$160,000.00

Enhanced yield and cannabinoid production of homogenous medical marijuana plants

EF 2019-20

Résumé
This research indicated in this proposal will produce critical knowledge relevant for the rapidly-expanding Cannabis industry, to provide high quality plant material with consistent cannabinoid concentrations. The project will address three knowledge gaps: 1) identifying Cannabis cultivars quickly, based on genetic and metabolomics markers, for quality control purposes; 2) stabilizing genetics of popular Cannabis cultivars and developing methods for propagating these lines via seeds; 3) altering yield, cannabinoid concentration and plant disease resistance using a microbial signal compound. This research is important because Cannabis producers must be able to grow consistent plant material for medical use in order to provide reliable doses (amount and composition) of cannabinoids when it is prescribed as a pharmaceutical-grade drug. Furthermore, plant disease resistance against powdery mildew must be addressed, since currently few registered control products are available, resulting in significant yield and quality reductions; the proposed method in this research project would also not leave chemical traces on flowers that will be used for human consumption. This research is important to 1) Cannabis producers, 2) clinicians and 3) patients. Cannabis producers will benefit from reduced yield losses; clinicians will benefit from a wider range of consistent Cannabis products that can be evaluated in clinical trials for treatment of a variety of medical conditions; patients will benefit from improved access to a range of high-quality Cannabis-based pharmaceutical products. The anticipated outcomes of this project are 1) a rapid and inexpensive identification system for Cannabis strains based on genetics and metabolites, 2) a method for producing genetically identical female Cannabis seeds, and 3) a novel strategy for regulating cannabinoid concentrations and composition and powdery mildew control in Cannabis. RavenQuest Biomed, the industrial partner, will benefit through improved production methods and consistent and well characterized plant genetics. Canada will benefit by using this knowledge to position itself as a world leader in production of high-quality medical Cannabis, increased tax revenues from Cannabis sales.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
517552-2017
Name nom
Smith, Donald
Department département
Plant Science
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2017
Award amount
160000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1209
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Agriculture
Area of application fr
Agriculture
Research subject code
4903
Research subject group en
Plant and treebiology
Research subject group fr
Biologie végétale et des arbres
Research subject en
Plant growth and development
Research subject fr
Croissance et développement des végétaux
Installment
inst:2 - 2
Partie
2
Nb partie
2
Application title
Enhanced yield and cannabinoid production of homogenous medical marijuana plants
Keyword
NSERC
Application summary
This research indicated in this proposal will produce critical knowledge relevant for the rapidly-expanding Cannabis industry, to provide high quality plant material with consistent cannabinoid concentrations. The project will address three knowledge gaps: 1) identifying Cannabis cultivars quickly, based on genetic and metabolomics markers, for quality control purposes; 2) stabilizing genetics of popular Cannabis cultivars and developing methods for propagating these lines via seeds; 3) altering yield, cannabinoid concentration and plant disease resistance using a microbial signal compound. This research is important because Cannabis producers must be able to grow consistent plant material for medical use in order to provide reliable doses (amount and composition) of cannabinoids when it is prescribed as a pharmaceutical-grade drug. Furthermore, plant disease resistance against powdery mildew must be addressed, since currently few registered control products are available, resulting in significant yield and quality reductions; the proposed method in this research project would also not leave chemical traces on flowers that will be used for human consumption. This research is important to 1) Cannabis producers, 2) clinicians and 3) patients. Cannabis producers will benefit from reduced yield losses; clinicians will benefit from a wider range of consistent Cannabis products that can be evaluated in clinical trials for treatment of a variety of medical conditions; patients will benefit from improved access to a range of high-quality Cannabis-based pharmaceutical products. The anticipated outcomes of this project are 1) a rapid and inexpensive identification system for Cannabis strains based on genetics and metabolites, 2) a method for producing genetically identical female Cannabis seeds, and 3) a novel strategy for regulating cannabinoid concentrations and composition and powdery mildew control in Cannabis. RavenQuest Biomed, the industrial partner, will benefit through improved production methods and consistent and well characterized plant genetics. Canada will benefit by using this knowledge to position itself as a world leader in production of high-quality medical Cannabis, increased tax revenues from Cannabis sales.